BRPI1014877B8 - compostos diamida tendo antagonista do receptor muscarínico e atividade agonista do receptor ß2 adrenérgico, composição farmacêutica e seu uso - Google Patents

compostos diamida tendo antagonista do receptor muscarínico e atividade agonista do receptor ß2 adrenérgico, composição farmacêutica e seu uso

Info

Publication number
BRPI1014877B8
BRPI1014877B8 BRPI1014877A BRPI1014877A BRPI1014877B8 BR PI1014877 B8 BRPI1014877 B8 BR PI1014877B8 BR PI1014877 A BRPI1014877 A BR PI1014877A BR PI1014877 A BRPI1014877 A BR PI1014877A BR PI1014877 B8 BRPI1014877 B8 BR PI1014877B8
Authority
BR
Brazil
Prior art keywords
compounds
receptor antagonist
agonist activity
pharmaceutical composition
adrenergic receptor
Prior art date
Application number
BRPI1014877A
Other languages
English (en)
Inventor
Hughes Adam
Byun Daniel
L Stangeland Eric
R Jacobsen John
Fleury Melissa
D Wilson Richard
Yen Rose
Chen Yan
Original Assignee
Theravance Respiratory Co Llc
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42272140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1014877(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Theravance Respiratory Co Llc, Theravance Inc filed Critical Theravance Respiratory Co Llc
Publication of BRPI1014877A2 publication Critical patent/BRPI1014877A2/pt
Publication of BRPI1014877A8 publication Critical patent/BRPI1014877A8/pt
Publication of BRPI1014877B1 publication Critical patent/BRPI1014877B1/pt
Publication of BRPI1014877B8 publication Critical patent/BRPI1014877B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

compostos diamida tendo antagonista do receptor muscarínico e atividade agosta do receptor (beta)2 adrenégico esta invenção refere-se a um composto de fórmula i: i ou a um sal farmaceuticamente aceitável do mesmo. tais compostos possuem tanto atividade antagonista do receptor muscarínico quanto agonista do receptor (beta)2 adrenérgico. a invenção também refere-se ás composições farmacêuticas compreendendo tais compostos, processos e intermediários para preparação de tais compostos, e métodos de usar tais compostos como agentes brocodilatadores para tratar doenças pulmorares.
BRPI1014877A 2009-04-23 2010-04-16 compostos diamida tendo antagonista do receptor muscarínico e atividade agonista do receptor ß2 adrenérgico, composição farmacêutica e seu uso BRPI1014877B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17203909P 2009-04-23 2009-04-23
US61/172,039 2009-04-23
PCT/US2010/031356 WO2010123766A1 (en) 2009-04-23 2010-04-16 DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND β2 ADRENERGIC RECEPTOR AGONIST ACTIVITY

Publications (4)

Publication Number Publication Date
BRPI1014877A2 BRPI1014877A2 (pt) 2016-04-12
BRPI1014877A8 BRPI1014877A8 (pt) 2018-03-13
BRPI1014877B1 BRPI1014877B1 (pt) 2020-11-10
BRPI1014877B8 true BRPI1014877B8 (pt) 2021-05-25

Family

ID=42272140

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1014877A BRPI1014877B8 (pt) 2009-04-23 2010-04-16 compostos diamida tendo antagonista do receptor muscarínico e atividade agonista do receptor ß2 adrenérgico, composição farmacêutica e seu uso

Country Status (31)

Country Link
US (14) US8138345B2 (pt)
EP (3) EP2599778B1 (pt)
JP (3) JP5671006B2 (pt)
KR (1) KR101769061B1 (pt)
CN (2) CN102405218B (pt)
AR (1) AR076412A1 (pt)
AU (1) AU2010239522B2 (pt)
BR (1) BRPI1014877B8 (pt)
CA (1) CA2758505C (pt)
CL (1) CL2011002637A1 (pt)
CO (1) CO6440584A2 (pt)
CY (2) CY1119008T1 (pt)
DK (3) DK2421849T3 (pt)
ES (3) ES2417339T3 (pt)
HR (3) HRP20130468T1 (pt)
HU (2) HUE042975T2 (pt)
IL (1) IL215554A (pt)
LT (2) LT3210981T (pt)
MX (1) MX2011011156A (pt)
MY (1) MY158339A (pt)
NZ (1) NZ595850A (pt)
PL (3) PL3210981T3 (pt)
PT (3) PT2599778T (pt)
RU (2) RU2543716C2 (pt)
SG (1) SG175330A1 (pt)
SI (3) SI2421849T1 (pt)
SM (3) SMT201900168T1 (pt)
TR (1) TR201903556T4 (pt)
TW (2) TWI513693B (pt)
WO (1) WO2010123766A1 (pt)
ZA (1) ZA201107743B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2599778T (pt) 2009-04-23 2017-06-06 Theravance Respiratory Co Llc Compostos de diamida possuindo actividade antagonista do receptor muscarínico e agonista do receptor adrenérgico beta 2
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
AR083115A1 (es) * 2010-09-30 2013-01-30 Theravance Inc Sales oxalato cristalinas de un compuesto diamida
HRP20151317T1 (hr) 2011-06-10 2016-01-01 Chiesi Farmaceutici S.P.A. Spojevi koji pokazuju aktivnost prema antagonistima muskarinskog receptora i beta2 adrenergiäśnog receptora
RU2606121C2 (ru) 2011-06-10 2017-01-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Соединения, обладающие антагонистической активностью в отношении мускариновых рецепторов и агонистической активностью в отношении бета2-адренорецепторов
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP3345904B1 (en) 2012-12-06 2020-07-29 Chiesi Farmaceutici S.p.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
KR102156441B1 (ko) 2012-12-06 2020-09-17 키에시 파르마슈티시 엣스. 피. 에이. 무스카린성 수용체 길항제 및 베타2 아드레날린성 수용체 효능제 활성을 가지는 화합물
AU2013360866A1 (en) 2012-12-18 2015-07-02 Almirall, S.A. New cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activity
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
CN104030933A (zh) * 2014-05-16 2014-09-10 烟台恒迪克能源科技有限公司 一种β-异烷醇基氨基戊酸环己胺的合成方法
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
TWI703138B (zh) 2015-02-12 2020-09-01 義大利商吉斯藥品公司 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物
CN107074816B (zh) * 2015-03-27 2020-07-17 四川海思科制药有限公司 一种杂环衍生物及其制备方法和在医药上的用途
TW201702225A (zh) * 2015-05-14 2017-01-16 Sichuan Haisco Pharmaceutical Co Ltd 具有β２受體激動及Ｍ受體拮抗活性的含氮雜螺環衍生物及其在醫藥上的用途
CN107108502A (zh) * 2015-05-14 2017-08-29 四川海思科制药有限公司 具有β2受体激动及M受体拮抗活性的联苯衍生物及其在医药上的用途
AR104828A1 (es) 2015-06-01 2017-08-16 Chiesi Farm Spa COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO
WO2017093208A1 (en) 2015-12-03 2017-06-08 Chiesi Farmaceutici S.P.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
CN107849019A (zh) * 2016-01-22 2018-03-27 四川海思科制药有限公司 一种氮杂环酰胺衍生物及其制备方法和在医药上的用途
EP3484879B1 (en) 2016-07-13 2020-12-30 Chiesi Farmaceutici S.p.A. Hydroxyquinolinone compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
JP6963616B2 (ja) 2016-12-14 2021-11-10 ベイジン ショウバイ ファーマシューティカル カンパニー，リミティッド ４級アンモニウム塩構造を有する二官能性化合物
US11065235B2 (en) 2017-05-19 2021-07-20 Council Of Scientific & Industrial Research Substituted methanopyrido [2, 1-a] isoindolones as mAChR modulators for treating various associated pathophysiological conditions and process for preparation thereof
WO2020047225A1 (en) 2018-08-30 2020-03-05 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease
US10562930B1 (en) * 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
CN117924216A (zh) * 2024-01-12 2024-04-26 王叔和生物医药(武汉)有限公司 一种1-哌啶丙酸的合成方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
MXPA02005596A (es) * 1999-12-07 2004-09-10 Theravance Inc Derivados de carbamato con actividad antagonista para el rerceptor muscarinico.
UA73543C2 (uk) * 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
EP2067784A3 (en) 2000-08-05 2012-08-22 Glaxo Group Limited 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivatives as anti-inflammatory agents
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
WO2003049518A1 (fr) * 2001-12-04 2003-06-12 Tokyo R & D Co., Ltd. Alimentation de courant
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
CN101239969B (zh) * 2003-02-14 2011-07-20 施万制药 联苯衍生物
ES2289691T3 (es) 2004-01-22 2008-02-01 Pfizer, Inc. Derivados de sulfonamida para el tratamiento de enfermedades.
WO2005080375A1 (en) * 2004-02-13 2005-09-01 Theravance, Inc. Crystalline form of a biphenyl compound
WO2005092861A1 (en) 2004-03-11 2005-10-06 Pfizer Limited Quinolinone derivatives pharmaceutical compositions containing them and their use
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
US7307076B2 (en) 2004-05-13 2007-12-11 Boehringer Ingelheim International Gmbh Beta agonists for the treatment of respiratory diseases
WO2006023460A2 (en) * 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
TWI374883B (en) * 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
WO2006023457A1 (en) * 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
AU2006337928B2 (en) 2006-02-08 2012-12-20 Fuji Oil Company, Limited Edible products with low content of saturated and trans unsaturated fats
GB0602778D0 (en) * 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
TW200811104A (en) * 2006-04-25 2008-03-01 Theravance Inc Crystalline forms of a dimethylphenyl compound
TW200811105A (en) * 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
WO2008096129A1 (en) 2007-02-07 2008-08-14 Argenta Discovery Ltd Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors
RU2539979C2 (ru) 2008-07-25 2015-01-27 Вайтаи Фармасьютиклз, Инк. Циклические ингибиторы 11бета-гидроксистероид-дегидрогеназы 1
PT2599778T (pt) 2009-04-23 2017-06-06 Theravance Respiratory Co Llc Compostos de diamida possuindo actividade antagonista do receptor muscarínico e agonista do receptor adrenérgico beta 2

Also Published As

Publication number Publication date
US10358433B2 (en) 2019-07-23
AU2010239522A1 (en) 2011-11-10
DK2599778T3 (en) 2017-06-26
US9975875B2 (en) 2018-05-22
JP2014210816A (ja) 2014-11-13
US20160361304A1 (en) 2016-12-15
US20170226082A1 (en) 2017-08-10
PT3210981T (pt) 2019-04-01
EP2599778A1 (en) 2013-06-05
IL215554A (en) 2014-08-31
US9000173B2 (en) 2015-04-07
TR201903556T4 (tr) 2019-04-22
CN103936716A (zh) 2014-07-23
PT2599778T (pt) 2017-06-06
CY1119008T1 (el) 2018-01-10
US9682957B2 (en) 2017-06-20
SI3210981T1 (sl) 2019-05-31
US9771350B2 (en) 2017-09-26
EP3210981B1 (en) 2019-01-02
CY1121601T1 (el) 2020-05-29
LT3210981T (lt) 2019-04-10
US20150274697A1 (en) 2015-10-01
SI2421849T1 (sl) 2013-07-31
TW201041866A (en) 2010-12-01
HUE042975T2 (hu) 2019-07-29
RU2543716C2 (ru) 2015-03-10
US20130331364A1 (en) 2013-12-12
CN102405218B (zh) 2014-06-04
HRP20170960T1 (hr) 2017-09-22
US20210024493A1 (en) 2021-01-28
US8551978B2 (en) 2013-10-08
EP2421849A1 (en) 2012-02-29
CA2758505C (en) 2017-03-07
US9394275B2 (en) 2016-07-19
US8138345B2 (en) 2012-03-20
WO2010123766A1 (en) 2010-10-28
AU2010239522B2 (en) 2015-07-02
SG175330A1 (en) 2011-11-28
HK1165799A1 (en) 2012-10-12
US8816088B2 (en) 2014-08-26
US9572802B2 (en) 2017-02-21
US20200165223A1 (en) 2020-05-28
EP2599778B1 (en) 2017-04-12
TWI513693B (zh) 2015-12-21
RU2011147374A (ru) 2013-05-27
BRPI1014877A8 (pt) 2018-03-13
RU2015101032A (ru) 2015-06-27
MY158339A (en) 2016-09-30
CL2011002637A1 (es) 2012-04-27
US20170362200A1 (en) 2017-12-21
BRPI1014877B1 (pt) 2020-11-10
ES2417339T3 (es) 2013-08-07
KR20110138292A (ko) 2011-12-26
MX2011011156A (es) 2011-11-04
PL2421849T3 (pl) 2013-08-30
JP5965440B2 (ja) 2016-08-03
ES2635358T3 (es) 2017-10-03
SMT201900168T1 (it) 2019-05-10
TWI570115B (zh) 2017-02-11
PL2599778T3 (pl) 2018-01-31
US10138220B1 (en) 2018-11-27
HRP20190417T1 (hr) 2019-04-19
CN103936716B (zh) 2016-09-07
US20170096412A1 (en) 2017-04-06
JP2012524783A (ja) 2012-10-18
US20190300504A1 (en) 2019-10-03
HUE035049T2 (en) 2018-05-02
US20130137665A1 (en) 2013-05-30
DK2421849T3 (da) 2013-07-01
JP2015147807A (ja) 2015-08-20
US10590107B2 (en) 2020-03-17
SMT201300060B (it) 2013-07-09
US20190047984A1 (en) 2019-02-14
BRPI1014877A2 (pt) 2016-04-12
KR101769061B1 (ko) 2017-08-17
CO6440584A2 (es) 2012-05-15
NZ595850A (en) 2013-05-31
LT2599778T (lt) 2017-08-25
EP3210981A1 (en) 2017-08-30
JP5671006B2 (ja) 2015-02-18
DK3210981T3 (en) 2019-04-01
HRP20130468T1 (en) 2013-06-30
PT2421849E (pt) 2013-05-27
RU2015101032A3 (pt) 2018-07-30
AR076412A1 (es) 2011-06-08
RU2676686C2 (ru) 2019-01-10
PL3210981T3 (pl) 2019-06-28
ZA201107743B (en) 2012-06-27
EP2421849B1 (en) 2013-04-03
TW201546057A (zh) 2015-12-16
CA2758505A1 (en) 2010-10-28
US20100273755A1 (en) 2010-10-28
IL215554A0 (en) 2011-12-29
ES2715965T3 (es) 2019-06-07
US10836744B2 (en) 2020-11-17
SI2599778T1 (sl) 2017-08-31
SMT201700305T1 (it) 2017-09-07
CN102405218A (zh) 2012-04-04
US20140323733A1 (en) 2014-10-30

Similar Documents

Publication Publication Date Title
CO6440584A2 (es) Compuestos diamida que tienen actividad como antagonistas de los receptores muscarínicos y como agonistas de los receptores adrenérgicos beta 2
BRPI0607015A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto
BRPI0708490B8 (pt) composto, composição farmacêutica, processo para preparar um composto da fórmula (i), e uso de um composto
BRPI0714315B8 (pt) arilamidas substituídas com tetrazol, seu uso e composição farmacêutica que as compreende
EA201170473A1 (ru) Морфинановые соединения
EA201000024A1 (ru) Новые производные дикарбоновых кислот в качестве агонистов рецептора s1p1
BRPI0607796A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparação e uso do mesmo, e, composição farmacêutica
BRPI0512058A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto
CY1110922T1 (el) Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις
MX2010002171A (es) Compuestos 8-azabiciclo[3.2.1] octil-2 hidroxibenzamida como antagonistas de los receptores opioides mu.
MX2010005997A (es) Derivados de aminobenzamida como agentes utiles para el control de parasitos de animales.
BRPI0821611A8 (pt) Derivado de 3-carboxipropil-aminotetralina e compostos relacionados como antagonistas do receptor opióide mu
EA201070916A1 (ru) Двойные фармакофоры - pde4-мускариновые антагонисты
ATE473961T1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
BRPI0611202C1 (pt) compostos de benzimidazola-carboxamida como agonistas do receptor 5-ht4
BR112013012665A2 (pt) composto de fórmula (i), ou um sal, pró-droga ou solvato do mesmo e composição farmacêutica
PT1861360E (pt) Derivados de pirrolidina como antagonistas de receptores h3 de histamina
ATE523488T1 (de) Histamin-h3-rezeptor-mittel, deren herstellung und therapeutische verwendung
MX2010007967A (es) N-[3-bromo-2-cloro-4-(4,5-dihidro-1h-imidazol-2-ilmetil)-fenil]-m etansulfoamida como agonista parcial alfa-1 a adrenergico para el tratamiento de la incontinencia.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: THERAVANCE RESPIRATORY COMPANY, LLC (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/04/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 13A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2718 DE 07-02-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.